Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer
Kunigara, Manika Putri
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Epidemiology Profile of Stage IV Ovarian Cancer in Dharmais National Cancer Hospital: An Observational Study Tadjoedin, Hilman; Suryana, Kresna Dharma; Hanafi, Widyorini Lestari Hutami; Kunigara, Manika Putri; Shiba, Alyssa Fairudz
Indonesian Journal of Cancer Vol 19, No 1 (2025): March
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i1.1308

Abstract

Background: Stage IV ovarian cancer showed a low 5-year survival rate, around 31%. Regrettably, the unclear symptoms and the ineffectiveness of early detection result in many patients being diagnosed with stage IV. Moreover, establishing a stage IV diagnosis is challenging and tricky. This study aims to provide a comprehensive overview of the clinical, laboratory, histopathological, and survival characteristics of stage IV ovarian cancer patients.Method: A cross-sectional study with a descriptive observational design, 100 of 1520 subjects gathered from the Cancer Registry of Dharmais National Cancer Hospital between January 2018 and December 2022, conducted on stage IV ovarian cancer patients who were not accompanied by primary cancer at other sites.Results: Among the 100 study subjects, 76.0% were aged 40–60 years, with a median age of 49.5 years. Most had a normal nutritional status (39.0%) or were underweight (34.0%). Comorbidities were present in 40.0% of the subjects, with hypertension being the most common (57.5%). The initial symptoms were abdominal enlargement in 74.0% of subjects, with 43.0% reporting shortness of breath. Laboratory examinations revealed that the majority had hemoglobin levels 10 mg/dL (90.0%), serum creatinine levels 1.2 mg/dL (90.0%), and D-Dimer levels 2000 ng/ mL (69.0%). Histopathological analysis identified high-grade serous carcinoma (HGSC) in 24.0% and clear cell carcinoma in 19.0% of subjects. The most common metastatic sites were the pleura (44.0%), liver (41.0%), and lungs (25.0%). Around 48.0% and 41.0% had surgery only and surgery with adjuvant chemotherapy, respectively. The majority of the outcomes (91.0%) indicated that patients with stage IV ovarian cancer did not survive and the median survival among the subjects was 4 months.Conclusion: The majority of stage IV ovarian cancer patients were aged 40–60 years, with abdominal enlargement as the initial symptoms, elevated D-Dimer levels, HGSC as the predominant histopathological type, and a high mortality rate as the outcome. Further research is recommended to explore additional variables and analyze factors contributing to mortali
The Difference between Chronic Myeloid Leukemia before and during the COVID-19 Pandemic: A Retrospective Study from Dharmais Cancer Center Tadjoedin, Hilman; Suryana, Kresna Dharma; Hadisantoso, Dwi Wahyunianto; Siregar, Nia Novianti; Djamal, Rizky Syawaluddin; Setiawan, Lyana; Hartono, Bryan Arista; Kunigara, Manika Putri
Indonesian Journal of Cancer Vol 19, No 4 (2025): December
Publisher : http://dharmais.co.id/

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v19i4.1365

Abstract

Background: Chronic myeloid leukemia (CML) is a rare disease, with a global incidence rate ranging from 10 to 15 cases per 1,000,000 population annually, constituting approximately 15% of all adult leukemia. The achievement of complete response in CML patients has been affected by the COVID-19 pandemic. This study aimed to determine differences in characteristics, survival, and complete hematological response (CHR) in CML patients before and after the COVID-19 pandemic at Dharmais Cancer Hospital.Method: A cohort retrospective was conducted using medical records among CML patients diagnosed and treated in 2018 to 2022 in Dharmais Cancer Hospital. Demographic, characteristics, and survival were described. Overall survival was analyzed using Kaplan-Meier and log-rank test, and bivariate analysis was used with the Chi-square and Fisher's exact test. Patients aged 18 years with CML confirmed by bone marrow analysis, and detected fusion of BCR-ABL were included, and multiple malignancies were excluded.Results: The study was conducted on 108 subjects (56 vs. 52, before and during the pandemic, respectively). The demographic characteristics in both periods showed that the majority of subjects were male (59.8% vs. 40.2%), had normal BMI (58.1% vs 41.9%), and had no comorbidities. However, there was a difference in age distribution. The subjects before the pandemic were predominantly over 40 years, while those during the pandemic were 18-39 years. A total of 91/108 subjects survived (49.5% before vs. 50.5% during the pandemic). The median overall survival was 55 vs. 52 months, with a p-value of 0.173. No significant association was found between the study period or history of COVID-19 infection and CHR. However, a significant association was observed between the CML phase and outcomes.Conclusion: No significant differences were observed in demographic or clinical characteristics, overall survival, or CHR among CML patients before and during the COVID-19 pandemic.
Co-Authors Djamal, Rizky Syawaluddin Hadisantoso, Dwi Wahyunianto Hanafi, Widyorini Lestari Hutami Hartono, Bryan Arista HILMAN TADJOEDIN, HILMAN Lyana Setiawan Nia Novianti Siregar, Nia Novianti Shiba, Alyssa Fairudz Suryana, Kresna Dharma